<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Causes Control</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Causes Control</journal-id><journal-title-group><journal-title>Cancer Causes &#x00026; Control</journal-title></journal-title-group><issn pub-type="ppub">0957-5243</issn><issn pub-type="epub">1573-7225</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39827416</article-id><article-id pub-id-type="pmc">PMC12098201</article-id>
<article-id pub-id-type="publisher-id">1960</article-id><article-id pub-id-type="doi">10.1007/s10552-025-01960-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>The impact of socioeconomic status on glioma survival: a retrospective analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>S&#x000f6;derlund</surname><given-names>Maria</given-names></name><address><email>maria.el.eriksson@umu.se</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Almqvist</surname><given-names>Carl</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Sj&#x000f6;str&#x000f6;m</surname><given-names>Olle</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Dahlin</surname><given-names>Anna M.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Sj&#x000f6;str&#x000f6;m</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Numan Hellquist</surname><given-names>Barbro</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Melin</surname><given-names>Beatrice</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Sandstr&#x000f6;m</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05kb8h459</institution-id><institution-id institution-id-type="GRID">grid.12650.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 1034 3451</institution-id><institution>Department of Diagnostics and Intervention, Oncology, </institution><institution>Ume&#x000e5; University, </institution></institution-wrap>SE-901 87, Ume&#x000e5;, Sweden </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>36</volume><issue>6</issue><fpage>577</fpage><lpage>586</lpage><history><date date-type="received"><day>6</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>6</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">Although sociodemographic factors such as socioeconomic status (SES), travel time to health care, cohabitation status, and region of residence are observed to influence incidence and survival for several types of cancers, it is unclear whether similar effects have been observed in patients with glioma. This study investigates whether these factors affect survival for glioma patients.</p></sec><sec><title>Methods</title><p id="Par2">In this retrospective study, the Swedish National Quality Registry for Brain Tumors was used to identify 1,276 patients with glioma WHO grade I&#x02013;IV for whom data were deposited between 2009 and 2013. The RISK North database, which links data from the National Cancer Quality Register with citizen demographic data from the Longitudinal Integration Database for Health Insurance and Labor Market Studies (LISA), the Total Population Registry (TPR), and the Geography Database (GD), was utilized to assess survival in patients with glioma in relation to education level, cohabitation status, travel time to regional hospitals, and region of residence.</p></sec><sec><title>Results</title><p id="Par3">In the multivariable analysis, longer survival was observed among WHO grade III-IV glioma patients with higher education level (middle school (ref) HR: 1, high school HR: 0.81 CI [0.67&#x02013;0.98], <italic>p</italic>&#x02009;=&#x02009;0.033; university/college HR: 0.81 CI [0.66&#x02013;1.00], <italic>p</italic>&#x02009;=&#x02009;0.048). Survival was not associated with travel time, cohabitation status, or region of residence in the multivariable survival analysis.</p></sec><sec><title>Conclusion</title><p id="Par4">Low education level was associated with reduced survival for patients with glioma WHO grade III and IV in multivariable survival analyses, but no differences in survival were found in relation to travel time, cohabitation status, or region of residence.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s10552-025-01960-1.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Glioma</kwd><kwd>Survival</kwd><kwd>Socioeconomic status</kwd><kwd>Education level</kwd><kwd>Travel time</kwd><kwd>Cohabitation status</kwd><kwd>Region of residence</kwd></kwd-group><funding-group><award-group><funding-source><institution>J&#x000e4;mtland County Cancer and Nursing Fund</institution></funding-source><award-id>750, 2038</award-id><principal-award-recipient><name><surname>S&#x000f6;derlund</surname><given-names>Maria</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>County Council of J&#x000e4;mtland-H&#x000e4;rjedalen</institution></funding-source><award-id>JLL-940255</award-id><principal-award-recipient><name><surname>S&#x000f6;derlund</surname><given-names>Maria</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>The Cancer Research Foundation in Northern Sweden</institution></funding-source><award-id>LP17-2158, AMP 20-1017, AMP 21-1033</award-id><principal-award-recipient><name><surname>S&#x000f6;derlund</surname><given-names>Maria</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Ume&#x000e5; University Hospital Grant</institution></funding-source><award-id>7003839</award-id><principal-award-recipient><name><surname>Melin</surname><given-names>Beatrice</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Swedish Cancer Foundation</institution></funding-source><award-id>CAN 2018/390</award-id><principal-award-recipient><name><surname>Melin</surname><given-names>Beatrice</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Swedish Research Council</institution></funding-source><award-id>2019-01566</award-id><principal-award-recipient><name><surname>Melin</surname><given-names>Beatrice</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Regional agreement between Ume&#x000e5; University and V&#x000e4;sterbotten County Council</institution></funding-source><award-id>RV-933065, RV-941694</award-id><principal-award-recipient><name><surname>Sandstr&#x000f6;m</surname><given-names>Maria</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Umea University</institution></funding-source></award-group><open-access><p>Open access funding provided by Umea University.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Switzerland AG 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par13">Brain tumors are classified into different tumor entities through histological and molecular parameters according to the 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System [<xref ref-type="bibr" rid="CR1">1</xref>]. Gliomas are categorized as low-grade (grade 1&#x02013;2) or high-grade (grade 3&#x02013;4). Glioblastoma (WHO grade 4) is the most common and most malignant glioma.</p><p id="Par14">There is evidence to suggest that some nonbiological indicators predict cancer incidence and outcomes. Socioeconomic status (SES), for which level of education is commonly used as a proxy, often contributes to health disparities [<xref ref-type="bibr" rid="CR2">2</xref>]. Some studies report that high SES is associated with a higher incidence of glioma [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>], but others have not found an association [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Earlier studies indicate that SES is associated with the type of treatment [<xref ref-type="bibr" rid="CR7">7</xref>] and survival for glioma patients [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par15">Another potential factor influencing treatment and survival is the travel time taken to receive health care services. Travel burden for receiving treatment has been described for several cancers [<xref ref-type="bibr" rid="CR9">9</xref>], but not for glioma, and it has been found that travel time might affect treatment choices and participation in clinical studies [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Walker et al. found small prognostic differences for patients living in rural or urban areas [<xref ref-type="bibr" rid="CR8">8</xref>]. However, the relation of travel time with treatment and survival has not been extensively studied in glioma patients.</p><p id="Par16">Patients with brain tumors commonly have disabilities affecting cognition and decision making and are often dependent on help from others. For health care providers, it is therefore important to take the patients&#x02019; network into consideration. Being a cohabitant (i.e., living together with someone) has been investigated as a potential factor influencing cancer outcomes. One study showed that marital status was associated with earlier stage at diagnosis, a larger proportion of treatment with curative intent, and better disease-specific survival for patients with several types of cancer, but not including brain tumors [<xref ref-type="bibr" rid="CR12">12</xref>]. In patients with central nervous system (CNS) tumors, Dalton et al. found no difference in relative survival between married and divorced patients [<xref ref-type="bibr" rid="CR5">5</xref>]. For patients with glioblastoma, Xie et al. found marriage to be associated with a survival advantage [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par17">Finally, in the Swedish context, the potential relation between region of residence and cancer outcomes has been investigated. Differences between Swedish regions in incidence and survival have been described for several types of cancer but data were not reported for brain tumor patients separately [<xref ref-type="bibr" rid="CR14">14</xref>]. The North differs from the southern regions, as it has lower population density, and longer travel distances to health care services. The education level is higher in the southern regions than in the North [<xref ref-type="bibr" rid="CR15">15</xref>]. This variation in sociodemographic factors increases the importance of the regional comparison.</p><p id="Par18">This study investigates whether SES (estimated through highest completed level of education), travel time to the closest regional hospital, and cohabitation status affect the survival for patients with glioma and whether there are differences in survival between the North and three regions in southern Sweden.</p></sec><sec id="Sec2"><title>Materials and methods</title><p id="Par19">This retrospective observational study included all patients diagnosed with glioma WHO grade I&#x02013;IV registered in the National Quality Registry for Brain Tumors between 2009 and 2013 in the North of Sweden and the three southern regions with high registry coverage. The glioma patients in this study were diagnosed before 2013, and the tumors were therefore classified according to the 2007 WHO Classification, where tumor grade is written in Roman numerals (I&#x02013;IV) [<xref ref-type="bibr" rid="CR16">16</xref>].</p><sec id="Sec3"><title>Data sources and retrieval</title><p id="Par20">The National Quality Registry for Brain Tumors records primary brain tumors (except CNS lymphoma) in adults. The coverage of the quality registry is evaluated by the Regional Cancer Centres in Sweden, by comparing it with the National Cancer Registry, where it is mandatory to register all detected cases of cancer. The coverage was 98&#x02013;100% in the southern regions (Middle Sweden, Stockholm-Gotland, and Southeastern) and 97&#x02013;100% in the North between 2009 and 2013. The health care regions South and West had lower coverage (South: 4&#x02013;79%, West: 88&#x02013;98%). Therefore, data from the health care regions South and West were excluded from the analysis, following the approach taken by similar previous analyses using this registry [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. For this study, cases were selected using International Statistical Classification of Diseases and Related Health Problems (ICD)-7 code 193 (malignant neoplasm of the brain and other parts of the nervous system) [<xref ref-type="bibr" rid="CR19">19</xref>]. To identify patients with glioblastoma, Systematized Nomenclature of Medicine (SNOMED) code 94,403 was used. The date of diagnosis was defined as the date of the pathology report. Surgery was categorized as biopsy or resection. In case of resection, a judgment was made from the postoperative magnetic resonance imaging performed within 48&#x000a0;h after surgery as gross total or partial resection. Grade was obtained from the pathology report. Age at diagnosis, sex, smoking status, WHO performance status (PS) [<xref ref-type="bibr" rid="CR20">20</xref>], and type of surgery were retrieved from the quality registry. The data on WHO PS and smoking were incomplete (32% missing for WHO PS and 30% for smoking), and those variables were therefore omitted from further analysis.</p><p id="Par21">The RISK North database was constructed to study cancer treatment and survival in relation to sociodemographic factors in the Swedish population [<xref ref-type="bibr" rid="CR21">21</xref>]. This database combines data from several health care and demographic registries through the unique personal identity numbers that are assigned to all Swedish residents. In this study, data originating from the following sources were retrieved from the RISK North; the National Quality Registry for Brain Tumors, data on education level were retrieved from the Longitudinal Integration Database for Health Insurance and Labor Market Studies (LISA), data on cohabitation status were obtained from the Total Population Registry (TPR), and the Geography Database (GD) was used to obtain GPS coordinates for the patients&#x02019; home address. The TPR encompasses all inhabitants in Sweden and contains data on births, death, marital status, and migration [<xref ref-type="bibr" rid="CR22">22</xref>], the LISA registers information on occupation, education, and income for the adult Swedish population [<xref ref-type="bibr" rid="CR23">23</xref>], and the GD registers the geographical coordinates of the home address for all persons residing in Sweden.</p></sec><sec id="Sec4"><title>Sociodemographic covariates</title><p id="Par22">SES was defined using the highest completed level of education as a proxy. Education level was divided into three categories: middle school (up to 9 years of compulsory school), high school (secondary education of 2 or 3 years), and university/college. According to the International Standard Classification of Education (ISCED) 2011 that is commonly used for categorizing education level, middle school corresponds to ISCED 0&#x02013;2, high school to ISCED 2&#x02013;3, and university/college to ISCED 4&#x02013;8 [<xref ref-type="bibr" rid="CR24">24</xref>]. Cohabitation status was defined as living alone versus living with another adult. Travel time by car from the patient&#x02019;s home address to the regional hospital was estimated based on GPS coordinates using ArcGIS&#x000ae; Pro (2.1.2) and ArcGIS online (Esri, Redlands, CA, USA) and was categorized into ten-minute intervals. The regional hospital was defined as the closest hospital equipped to treat brain tumors (i.e., the closest hospital with a neurosurgical unit) in the health care region. The northern Swedish health care region (the North) consists of the four northernmost county councils (Norrbotten, V&#x000e4;sterbotten, J&#x000e4;mtland-H&#x000e4;rjedalen, and V&#x000e4;sternorrland). In this study, the Southern regions were defined as a group including the health care regions Middle Sweden, Stockholm-Gotland, and Southeastern.</p></sec><sec id="Sec5"><title>Statistical analyses</title><p id="Par23">The analyses were conducted with the study patients classified into WHO grade I&#x02013;II, WHO grade III&#x02013;IV, and WHO grade IV only (glioblastoma) subgroups. To test for differences in proportions, Pearson&#x02019;s chi-square test was used. To compare differences in means between groups, analysis of variance (ANOVA) was used. The type I error rate was set at 5%, and all tests were two-tailed. Cox proportional hazard analysis was used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) in a multivariable survival analysis of the association between survival, education level, travel time, cohabitation status, and region of residence considering the potential confounders sex, age at diagnosis, and extent of surgery. Survival time was calculated from the date of diagnosis to the date of death or last follow-up (2014-12-31). Statistical analyses were performed using R, version 3.6.0 (R Core Team, Vienna, Austria) [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Characteristics of the study patient cohort</title><p id="Par24">The population in the southern regions was larger than that in the North during the study period (4,951,823 vs. 878,706 as of 2013) (Online Resource 1). For the study cohort, we identified 1,276 patients with glioma WHO grade I&#x02013;IV from the National Quality Registry for Brain Tumors (2009&#x02013;2013). In total, 799 patients with glioblastoma, 214 patients with glioma WHO grade III, and 263 patients with glioma WHO grade I&#x02013;II were identified and included in subsequent analyses (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Characteristics of patients with glioma categorized by the WHO grading system</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Variable</th><th align="left" rowspan="2">Level</th><th align="left" colspan="3">Glioma WHO grade I&#x02013;II</th><th align="left" colspan="3">Glioma WHO grade III&#x02013;IV</th><th align="left" colspan="3">Glioblastoma (Glioma WHO grade IV)</th></tr><tr><th align="left">Northern Sweden</th><th align="left">Southern regions</th><th align="left">Total</th><th align="left">Northern Sweden</th><th align="left">Southern regions</th><th align="left">Total</th><th align="left">Northern Sweden</th><th align="left">Southern regions</th><th align="left">Total</th></tr></thead><tbody><tr><td align="left">Total</td><td align="left"><italic>n</italic></td><td char="." align="char">50</td><td char="." align="char">213</td><td char="." align="char">263</td><td char="." align="char">209</td><td char="." align="char">804</td><td char="." align="char">1,013</td><td char="." align="char">176</td><td char="." align="char">623</td><td char="." align="char">799</td></tr><tr><td align="left" colspan="11">Sex</td></tr><tr><td align="left">&#x000a0;Male</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">24 (48)</td><td char="." align="char">110 (52)</td><td char="." align="char">134 (51)</td><td char="." align="char">134 (64)</td><td char="." align="char">487 (61)</td><td char="." align="char">621 (61)</td><td char="." align="char">108 (61)</td><td char="." align="char">382 (61)</td><td char="." align="char">490 (61)</td></tr><tr><td align="left">&#x000a0;Female</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">26 (52)</td><td char="." align="char">103 (48)</td><td char="." align="char">129 (49)</td><td char="." align="char">75 (36)</td><td char="." align="char">317 (39)</td><td char="." align="char">392 (39)</td><td char="." align="char">68 (39)</td><td char="." align="char">241 (39)</td><td char="." align="char">309 (39)</td></tr><tr><td align="left">&#x000a0;Missing</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td></tr><tr><td align="left"><italic>Chi</italic><sup><italic>2</italic></sup><italic>-test</italic><sup><italic>a</italic></sup></td><td align="left"><italic>p</italic></td><td char="." align="char"/><td char="." align="char"><italic>0.76</italic></td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"><italic>0.39</italic></td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"><italic>1.00</italic></td><td char="." align="char"/></tr><tr><td align="left" colspan="11">Age at diagnosis (years)</td></tr><tr><td align="left">&#x000a0;18&#x02013;39</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">18 (36)</td><td char="." align="char">78 (37)</td><td char="." align="char">96 (36)</td><td char="." align="char">8 (4)</td><td char="." align="char">50 (6)</td><td char="." align="char">58 (6)</td><td char="." align="char">5 (3)</td><td char="." align="char">21 (3)</td><td char="." align="char">26 (3)</td></tr><tr><td align="left">&#x000a0;40&#x02013;59</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">15 (30)</td><td char="." align="char">87 (41)</td><td char="." align="char">102 (39)</td><td char="." align="char">53 (25)</td><td char="." align="char">275 (34)</td><td char="." align="char">328 (32)</td><td char="." align="char">41 (23)</td><td char="." align="char">210 (34)</td><td char="." align="char">251 (31)</td></tr><tr><td align="left">&#x000a0;60&#x02013;69</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">10 (20)</td><td char="." align="char">33 (15)</td><td char="." align="char">43 (16)</td><td char="." align="char">71 (34)</td><td char="." align="char">270 (34)</td><td char="." align="char">341 (34)</td><td char="." align="char">62 (35)</td><td char="." align="char">219 (35)</td><td char="." align="char">281 (35)</td></tr><tr><td align="left">&#x000a0;&#x02265;&#x02009;70</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">7 (14)</td><td char="." align="char">15 (7)</td><td char="." align="char">22 (8)</td><td char="." align="char">77 (37)</td><td char="." align="char">209 (26)</td><td char="." align="char">286 (28)</td><td char="." align="char">68 (39)</td><td char="." align="char">173 (28)</td><td char="." align="char">241 (30)</td></tr><tr><td align="left">&#x000a0;Missing</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td></tr><tr><td align="left"><italic>Chi</italic><sup><italic>2</italic></sup><italic>-test</italic><sup><italic>a</italic></sup></td><td align="left"><italic>p</italic></td><td char="." align="char"/><td char="." align="char"><italic>0.25</italic></td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"><italic>0.006</italic></td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"><italic>0.02</italic></td><td char="." align="char"/></tr><tr><td align="left" colspan="11">Extent of surgery</td></tr><tr><td align="left">&#x000a0;Gross total resection</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">16 (32)</td><td char="." align="char">98 (46)</td><td char="." align="char">114 (43)</td><td char="." align="char">42 (20)</td><td char="." align="char">331 (41)</td><td char="." align="char">373 (37)</td><td char="." align="char">38 (22)</td><td char="." align="char">273 (44)</td><td char="." align="char">311 (39)</td></tr><tr><td align="left">&#x000a0;Partial resection</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">17 (34)</td><td char="." align="char">81 (38)</td><td char="." align="char">98 (37)</td><td char="." align="char">78 (37)</td><td char="." align="char">248 (31)</td><td char="." align="char">326 (32)</td><td char="." align="char">68 (39)</td><td char="." align="char">186 (30)</td><td char="." align="char">254 (32)</td></tr><tr><td align="left">&#x000a0;Biopsy</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">17 (34)</td><td char="." align="char">33 (15)</td><td char="." align="char">50 (19)</td><td char="." align="char">89 (43)</td><td char="." align="char">188 (23)</td><td char="." align="char">277 (27)</td><td char="." align="char">70 (40)</td><td char="." align="char">133 (21)</td><td char="." align="char">203 (25)</td></tr><tr><td align="left">&#x000a0;Unknown</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">0 (0)</td><td char="." align="char">1 (0.5)</td><td char="." align="char">1 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">37 (5)</td><td char="." align="char">37 (4)</td><td char="." align="char">0 (0)</td><td char="." align="char">31 (5)</td><td char="." align="char">31 (4)</td></tr><tr><td align="left">&#x000a0;Missing</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td></tr><tr><td align="left"><italic>Chi</italic><sup><italic>2</italic></sup><italic>-test</italic><sup><italic>a</italic></sup></td><td align="left"><italic>p</italic></td><td char="." align="char"/><td char="." align="char"><italic>0.02</italic></td><td char="." align="char"/><td char="." align="char"/><td char="." align="char">&#x02009;&#x0003c;&#x02009;<italic>0.001</italic></td><td char="." align="char"/><td char="." align="char"/><td char="." align="char">&#x02009;&#x0003c;&#x02009;<italic>0.001</italic></td><td char="." align="char"/></tr><tr><td align="left" colspan="11">Education level</td></tr><tr><td align="left">&#x000a0;Middle school</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">14 (28)</td><td char="." align="char">31 (15)</td><td char="." align="char">45 (17)</td><td char="." align="char">56 (27)</td><td char="." align="char">202 (25)</td><td char="." align="char">258 (25)</td><td char="." align="char">49 (28)</td><td char="." align="char">162 (26)</td><td char="." align="char">211 (26)</td></tr><tr><td align="left">&#x000a0;High school</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">20 (40)</td><td char="." align="char">86 (40)</td><td char="." align="char">106 (40)</td><td char="." align="char">94 (45)</td><td char="." align="char">322 (40)</td><td char="." align="char">416 (41)</td><td char="." align="char">74 (42)</td><td char="." align="char">245 (39)</td><td char="." align="char">319 (40)</td></tr><tr><td align="left">&#x000a0;University/college</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">15 (30)</td><td char="." align="char">92 (43)</td><td char="." align="char">107 (41)</td><td char="." align="char">58 (28)</td><td char="." align="char">274 (34)</td><td char="." align="char">332 (33)</td><td char="." align="char">52 (30)</td><td char="." align="char">212 (34)</td><td char="." align="char">264 (33)</td></tr><tr><td align="left">&#x000a0;Missing</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">1 (2)</td><td char="." align="char">4 (2)</td><td char="." align="char">5 (2)</td><td char="." align="char">1 (0.5)</td><td char="." align="char">6 (1)</td><td char="." align="char">7 (1)</td><td char="." align="char">1 (0.6)</td><td char="." align="char">4 (0.6)</td><td char="." align="char">5 (1)</td></tr><tr><td align="left"><italic>Chi</italic><sup><italic>2</italic></sup><italic>-test</italic><sup><italic>a</italic></sup></td><td align="left"><italic>p</italic></td><td char="." align="char"/><td char="." align="char"><italic>0.05</italic></td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"><italic>0.2</italic></td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"><italic>0.53</italic></td><td char="." align="char"/></tr><tr><td align="left" colspan="11">Travel time (min)</td></tr><tr><td align="left">&#x000a0;&#x0003c;&#x02009;30</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">7 (14)</td><td char="." align="char">105 (49)</td><td char="." align="char">112 (43)</td><td char="." align="char">19 (9)</td><td char="." align="char">385 (48)</td><td char="." align="char">404 (40)</td><td char="." align="char">14 (8)</td><td char="." align="char">299 (48)</td><td char="." align="char">313 (39)</td></tr><tr><td align="left">&#x000a0;30&#x02013;59</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">0 (0)</td><td char="." align="char">39 (18)</td><td char="." align="char">39 (15)</td><td char="." align="char">4 (2)</td><td char="." align="char">159 (20)</td><td char="." align="char">163 (16)</td><td char="." align="char">4 (2)</td><td char="." align="char">124 (20)</td><td char="." align="char">128 (16)</td></tr><tr><td align="left">&#x000a0;60&#x02013;119</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">8 (16)</td><td char="." align="char">40 (19)</td><td char="." align="char">48 (18)</td><td char="." align="char">32 (15)</td><td char="." align="char">131 (16)</td><td char="." align="char">163 (16)</td><td char="." align="char">28 (16)</td><td char="." align="char">105 (17)</td><td char="." align="char">133 (17)</td></tr><tr><td align="left">&#x000a0;&#x02265;&#x02009;120</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">35 (70)</td><td char="." align="char">29 (14)</td><td char="." align="char">64 (24)</td><td char="." align="char">154 (74)</td><td char="." align="char">129 (16)</td><td char="." align="char">283 (28)</td><td char="." align="char">130 (74)</td><td char="." align="char">95 (15)</td><td char="." align="char">225 (28)</td></tr><tr><td align="left">&#x000a0;Missing</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td></tr><tr><td align="left"><italic>Chi</italic><sup><italic>2</italic></sup><italic>-test</italic><sup><italic>a</italic></sup></td><td align="left"><italic>p</italic></td><td char="." align="char"/><td char="." align="char">&#x02009;&#x0003c;&#x02009;<italic>0.001</italic></td><td char="." align="char"/><td char="." align="char"/><td char="." align="char">&#x02009;&#x0003c;&#x02009;<italic>0.001</italic></td><td char="." align="char"/><td char="." align="char"/><td char="." align="char">&#x02009;&#x0003c;&#x02009;<italic>0.001</italic></td><td char="." align="char"/></tr><tr><td align="left" colspan="11">Cohabitation status</td></tr><tr><td align="left">&#x000a0;Living alone</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">10 (20)</td><td char="." align="char">71 (33)</td><td char="." align="char">81 (31)</td><td char="." align="char">58 (28)</td><td char="." align="char">238 (30)</td><td char="." align="char">296 (29)</td><td char="." align="char">51 (29)</td><td char="." align="char">183 (29)</td><td char="." align="char">234 (29)</td></tr><tr><td align="left">&#x000a0;Not living alone</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">40 (80)</td><td char="." align="char">142 (67)</td><td char="." align="char">182 (69)</td><td char="." align="char">151 (72)</td><td char="." align="char">566 (70)</td><td char="." align="char">717 (71)</td><td char="." align="char">125 (71)</td><td char="." align="char">440 (71)</td><td char="." align="char">565 (71)</td></tr><tr><td align="left">&#x000a0;Missing</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td><td char="." align="char">0 (0)</td></tr><tr><td align="left"><italic>Chi</italic><sup><italic>2</italic></sup><italic>-test</italic><sup><italic>a</italic></sup></td><td align="left"><italic>p</italic></td><td char="." align="char"/><td char="." align="char"><italic>0.1</italic></td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"><italic>0.66</italic></td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"><italic>0.99</italic></td><td char="." align="char"/></tr><tr><td align="left" colspan="11">WHO PS<sup>b</sup></td></tr><tr><td align="left">&#x000a0;0</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">16 (32)</td><td char="." align="char">88 (41)</td><td char="." align="char">104 (40)</td><td char="." align="char">28 (13)</td><td char="." align="char">249 (31)</td><td char="." align="char">277 (27)</td><td char="." align="char">25 (14)</td><td char="." align="char">182 (29)</td><td char="." align="char">207 (26)</td></tr><tr><td align="left">&#x000a0;1</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">4 (8)</td><td char="." align="char">31 (15)</td><td char="." align="char">35 (13)</td><td char="." align="char">41 (20)</td><td char="." align="char">143 (18)</td><td char="." align="char">184 (18)</td><td char="." align="char">34 (19)</td><td char="." align="char">114 (18)</td><td char="." align="char">148 (19)</td></tr><tr><td align="left">&#x000a0;2</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">0 (0)</td><td char="." align="char">14 (7)</td><td char="." align="char">14 (5)</td><td char="." align="char">38 (18)</td><td char="." align="char">128 (16)</td><td char="." align="char">166 (16)</td><td char="." align="char">35 (20)</td><td char="." align="char">101 (16)</td><td char="." align="char">136 (17)</td></tr><tr><td align="left">&#x000a0;3</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">1 (2)</td><td char="." align="char">1 (0.5)</td><td char="." align="char">2 (1)</td><td char="." align="char">14 (7)</td><td char="." align="char">50 (6)</td><td char="." align="char">64 (6)</td><td char="." align="char">12 (7)</td><td char="." align="char">43 (7)</td><td char="." align="char">55 (7)</td></tr><tr><td align="left">&#x000a0;4</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">1 (2)</td><td char="." align="char">2 (1)</td><td char="." align="char">3 (1)</td><td char="." align="char">4 (2)</td><td char="." align="char">14 (2)</td><td char="." align="char">18 (2)</td><td char="." align="char">2 (1)</td><td char="." align="char">11 (2)</td><td char="." align="char">13 (2)</td></tr><tr><td align="left">&#x000a0;Missing</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">28 (56)</td><td char="." align="char">77 (36)</td><td char="." align="char">105 (40)</td><td char="." align="char">84 (40)</td><td char="." align="char">220 (27)</td><td char="." align="char">304 (30)</td><td char="." align="char">68 (39)</td><td char="." align="char">172 (28)</td><td char="." align="char">240 (30)</td></tr><tr><td align="left"><italic>Chi</italic><sup><italic>2</italic></sup><italic>-test</italic><sup><italic>a</italic></sup></td><td align="left"><italic>p</italic></td><td char="." align="char"/><td char="." align="char"><italic>0.22</italic></td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"><italic>0.02</italic></td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"><italic>0.001</italic></td><td char="." align="char"/></tr><tr><td align="left" colspan="11">Smoking</td></tr><tr><td align="left">&#x000a0;Never smoker</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">26 (52)</td><td char="." align="char">114 (54)</td><td char="." align="char">140 (53)</td><td char="." align="char">96 (46)</td><td char="." align="char">358 (45)</td><td char="." align="char">454 (45)</td><td char="." align="char">80 (45)</td><td char="." align="char">278 (45)</td><td char="." align="char">358 (45)</td></tr><tr><td align="left">&#x000a0;Ex-smoker</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">6 (12)</td><td char="." align="char">18 (8)</td><td char="." align="char">24 (9)</td><td char="." align="char">35 (17)</td><td char="." align="char">106 (13)</td><td char="." align="char">141 (14)</td><td char="." align="char">29 (16)</td><td char="." align="char">79 (13)</td><td char="." align="char">108 (14)</td></tr><tr><td align="left">&#x000a0;Current smoker</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">5 (10)</td><td char="." align="char">23 (11)</td><td char="." align="char">28 (11)</td><td char="." align="char">24 (11)</td><td char="." align="char">82 (10)</td><td char="." align="char">106 (10)</td><td char="." align="char">22 (13)</td><td char="." align="char">67 (11)</td><td char="." align="char">89 (11)</td></tr><tr><td align="left">&#x000a0;Missing</td><td align="left"><italic>n</italic> (%)</td><td char="." align="char">13 (26)</td><td char="." align="char">58 (27)</td><td char="." align="char">71 (27)</td><td char="." align="char">54 (26)</td><td char="." align="char">258 (32)</td><td char="." align="char">312 (31)</td><td char="." align="char">45 (26)</td><td char="." align="char">199 (32)</td><td char="." align="char">244 (31)</td></tr><tr><td align="left"><italic>Chi</italic><sup><italic>2</italic></sup><italic>-test</italic><sup><italic>a</italic></sup></td><td align="left"><italic>p</italic></td><td char="." align="char"/><td char="." align="char"><italic>0.89</italic></td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"><italic>0.27</italic></td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"><italic>0.30</italic></td><td char="." align="char"/></tr></tbody></table><table-wrap-foot><p><sup>a</sup>The chi<sup>2</sup>-test was used to assess differences between northern Sweden and the three southern regions</p><p><sup>b</sup>WHO PS&#x02009;=&#x02009;WHO performance status</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec8"><title>Multivariable survival analyses show better survival for patients with higher education level in glioma WHO grade III-IV but no differences for cohabitation status, travel time, or region</title><p id="Par25">A hazard analysis was conducted to determine whether the sociodemographic variables included in this study influence the survival of patients with glioma. In the multivariable model, survival in patients with glioma WHO grade III&#x02013;IV was significantly longer among patients with higher education level (middle school (ref) HR: 1; high school HR: 0.81 CI [0.67&#x02013;0.98], <italic>p</italic>&#x02009;=&#x02009;0.033; university/college HR: 0.81 CI [0.66&#x02013;1.00], <italic>p</italic>&#x02009;=&#x02009;0.048) but did not differ by travel time, cohabitation status, or region of residence (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Cox regression analysis of factors related to overall survival in 1013 patients with WHO grade III&#x02013;IV glioma (<bold>A</bold>) and 799 patients with glioblastoma (<bold>B</bold>)</p></caption><graphic xlink:href="10552_2025_1960_Fig1_HTML" id="MO1"/></fig></p><p id="Par26">For the glioblastoma subgroup, survival was significantly shorter for patients with older age at diagnosis (18&#x02013;39&#x000a0;years (ref) HR: 1; 40&#x02013;59&#x000a0;years HR: 1.33 CI [0.77&#x02013;2.30] <italic>p</italic>&#x02009;=&#x02009;0.305; 60&#x02013;69&#x000a0;years HR: 1.89 CI [1.09&#x02013;3.30] <italic>p</italic>&#x02009;=&#x02009;0.024;&#x02009;&#x02265;&#x02009;70&#x000a0;years HR: 3.38 CI [1.93&#x02013;5.90], <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and for patients with less extensive surgery (gross total resection (ref) HR: 1; partial resection HR: 1.56 CI [1.26&#x02013;1.90], <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; biopsy HR: 2.59 CI [2.08&#x02013;3.20], <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). In survival analysis for the glioblastoma subgroup, a similar inverse association by education level was noted as for grade III-IV but it was not statistically significant. Estimates for travel time, cohabitation status, or region of residence were not statistically significant. (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B).</p><p id="Par27">For patients with glioma WHO grade I&#x02013;II, older age at diagnosis was associated with shorter survival. In the same analysis, education level, travel time, cohabitation status, and region of residence were not associated with survival (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Cox regression analysis of factors related to overall survival in 263 patients with glioma WHO grade I&#x02013;II</p></caption><graphic xlink:href="10552_2025_1960_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec9"><title>Patients with glioma WHO grade III-IV living in the North were older, had less extensive surgery and longer distance to a regional hospital</title><p id="Par28">A comparison between the regions was made regarding sociodemographic factors to study regional differences. In the glioma WHO grade III&#x02013;IV subgroup and the glioblastoma subgroup, the age distribution differed between the regions, with the North having larger proportions of patients in the older age groups (<italic>p</italic>&#x02009;=&#x02009;0.006 for the glioma WHO grade III&#x02013;IV subgroup; <italic>p</italic>&#x02009;=&#x02009;0.02 for the glioblastoma subgroup). In the subgroup of patients with glioma WHO grade I&#x02013;II, the age distribution did not differ between regions (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par29">In terms of the extent of surgery, it was more common for patients in the North to receive less extensive surgery, with 40% of patients with glioblastoma receiving a biopsy as the only surgical procedure compared to 21% of patients in the southern regions (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par30">There was a tendency for patients with glioblastoma in the southern regions to have a better WHO PS than those in the North, but there were no apparent differences in smoking status between the regions (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par31">For all groups of patients, there were no significant differences in the highest completed level of education or in cohabitation status between patients in the North and those in the southern regions (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The mean travel time to a regional hospital was longer for patients in the North for all groups, and low SES was associated with a longer travel time for all groups (Online Resource 2).</p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par32">In this study, the multivariable survival analysis showed that patients with glioma WHO grade III-IV with the lowest SES (estimated through highest completed level of education) experienced the worst outcomes. However, no differences in survival according to travel time to a regional hospital, cohabitation status, or region of residence were found in the multivariable model for this population. For patients with lower-grade glioma (WHO grade I&#x02013;II) and for patients with glioblastoma, neither SES, travel time to a regional hospital, cohabitation status, nor region were associated with survival.</p><p id="Par33">The shorter survival time for patients with lower SES observed in this study is similar to the findings of Dalton et al., albeit those authors analyzed all types of CNS tumors together [<xref ref-type="bibr" rid="CR5">5</xref>]. These differences in survival related to SES might be associated with other known disease-related prognostic factors, comorbidities, or access to health care.</p><p id="Par34">A range of prognostic factors have been identified for patients with glioma WHO grade III and glioblastoma, including age, WHO PS, extent of surgery, postoperative treatment, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status, and isocitrate dehydrogenase (IDH) mutation [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>]. Dressler et al. studied sociodemographic factors and treatment decisions and found that old age, female sex, and low SES were associated with less access to full therapy [<xref ref-type="bibr" rid="CR7">7</xref>], and in another study, longer waiting times for surgery were reported for glioma patients with lower SES [<xref ref-type="bibr" rid="CR35">35</xref>]. In our multivariable model, SES was associated with survival despite adjusting for age and extent of surgery. Since data on WHO PS, postoperative treatment, MGMT methylation, and IDH mutation were missing in the study cohort, these variables were not included in the multivariable model.</p><p id="Par35">In theory, access to care in Sweden&#x000b4;s publicly funded health care system should be equal to that of all citizens. However, actual access to care is affected not only by the availability of care but also by financial factors (affordability), health care-seeking behavior (acceptability), and geographic factors (accessibility) [<xref ref-type="bibr" rid="CR36">36</xref>]. Health care-seeking behavior among patients with early cancer symptoms is associated with demographic factors, but a study by Svendsen et al. found no clear association with SES [<xref ref-type="bibr" rid="CR37">37</xref>]. The present study did not include data on when or how glioma was diagnosed in patients. Consequently, differences in health care-seeking behavior might explain the disparity in survival according to SES in our study.</p><p id="Par36">Longer travel times to the regional hospital were associated with older age and low SES in this study. In the multivariable analysis, no association between travel time and survival was found, which indicates that travel time to health care is not an independent prognostic factor for glioma. This study cannot conclude whether travel time impacts treatment decisions since treatment was not investigated in detail; however, no differences in survival related to travel time were observed in the multivariable analysis, which suggests that undertreatment was not related to travel time in this study cohort.</p><p id="Par37">Cohabitation status was not associated with survival in our study, but earlier studies on cohabitation status and glioma survival have presented discordant findings. Dalton et al. found no difference in survival related to marriage for patients with CNS tumors, but Xie et al. found a better survival for glioblastoma patients who were married [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Marriage might have a protective effect through improved mental, physical, and economic support and earlier diagnosis [<xref ref-type="bibr" rid="CR13">13</xref>]. Cohabitant patients should benefit from similar social and physical support as married patients, and a favorable prognosis should appear stronger when studying cohabitation status instead of marriage. The lack of an association between cohabitation status and survival in our study might be explained by good access to support from health care for patients who are not cohabitants.</p><p id="Par38">Finally, we found no difference in survival between the North and the southern regions despite several negative prognostic factors in the North, including higher age at diagnosis, a larger proportion of biopsies, and a tendency for worse WHO PS. We have no clear explanation for this finding. The quality registry data on age at diagnosis and surgery are most likely accurate. Reporting of WHO PS is more subjective, and it is possible that these data may not reflect a true difference between the regions. Other factors that could partly explain this finding include MGMT methylation, IDH mutation, postoperative treatment, and comorbidities.</p><sec id="Sec11"><title>Strengths and limitations</title><p id="Par39">This population-based study included all regions of Sweden with high coverage in the National Quality Registry for Brain Tumors. The access to health care and demographic registries in Sweden and the possibility of linking individual data from different sources using personal identity numbers represented another important strength of this study.</p><p id="Par40">The primary limitation of this study was the lack of data in the main study cohort on comorbidities, lifestyle factors (smoking), prognostic factors (e.g., IDH mutation, 1p19q deletion, and MGMT methylation), and postoperative treatment. Molecular pathological analyses were not available, as the quality registry data were collected before the implementation of the WHO 2016 classification.</p><p id="Par41">Estimation of SES through highest completed level of education might not always reflect true SES, and this was a potential limitation in this study.</p></sec></sec><sec id="Sec12"><title>Conclusion</title><p id="Par42">In this study of glioma prognosis, survival was significantly worse in patients with lower SES than in those with higher SES for WHO grade III-IV glioma. We found no significant differences in survival related to travel time to a regional hospital, cohabitation status, or region of residence (i.e., the North vs. the southern regions) in Sweden.</p></sec><sec id="Sec13" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="10552_2025_1960_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 56 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="10552_2025_1960_MOESM2_ESM.docx"><caption><p>Supplementary file2 (DOCX 60 KB)</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CNS</term><def><p id="Par5">Central Nervous System</p></def></def-item><def-item><term>GD</term><def><p id="Par6">Geography Database</p></def></def-item><def-item><term>ISCED</term><def><p id="Par7">International Standard Classification of Education</p></def></def-item><def-item><term>LISA</term><def><p id="Par8">Longitudinal Integration Database for Health Insurance and Labor Market Studies</p></def></def-item><def-item><term>PS</term><def><p id="Par9">Performance Status</p></def></def-item><def-item><term>SES</term><def><p id="Par10">Socioeconomic Status</p></def></def-item><def-item><term>TPR</term><def><p id="Par11">Total Population Registry</p></def></def-item><def-item><term>WHO</term><def><p id="Par12">World Health Organization</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>Experimental design: BM, BNH, OS, and AD. Analysis: BNH, MS&#x000f6;, CA, MSa, and&#x000a0;BM. Interpretation of the data: All authors. Drafting of the first version of the manuscript: MS&#x000f6;, MSa, and BM. Revision of the manuscript to the final version: All authors.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by Umea University. This study was funded with grants from the Regional Cancer Centre of Northern Sweden, the Cancer Research Foundation in Northern Sweden (LP17-2158, AMP 20-1017, and AMP 21-1033 to M.S&#x000f6;.), regional agreement between Ume&#x000e5; University and V&#x000e4;sterbotten County Council (RV-933065, and RV-941694 to M.Sa.), the Swedish Research Council (2019-01566 to B.M.), the Swedish Cancer Foundation (CAN 2018/390 to B.M.), Ume&#x000e5; University Hospital Grant (7003839 to B.M.), J&#x000e4;mtland County Cancer and Nursing Fund (no. 750 and 2038 to M.S&#x000f6;.), and the County Council of J&#x000e4;mtland-H&#x000e4;rjedalen (JLL-940255 to M.S&#x000f6;.).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data analyzed in this study are available from the National Quality Registry for Brain Tumors, the LISA, the TPR, and the GD. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the authors upon reasonable request with the permission of the National Quality Registry for Brain Tumors, the LISA, the TPR, or the GD.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par43">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethical approval</title><p id="Par44">The Regional Board of Ethics in Ume&#x000e5; approved the creation of the RISK North database and the overall aim of the study (2014/278-31). Delivery and linking of data were approved by the steering committees and authorities for each included registry.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Perry</surname><given-names>A</given-names></name><name><surname>Wesseling</surname><given-names>P</given-names></name><name><surname>Brat</surname><given-names>DJ</given-names></name><name><surname>Cree</surname><given-names>IA</given-names></name><name><surname>Figarella-Branger</surname><given-names>D</given-names></name><name><surname>Hawkins</surname><given-names>C</given-names></name><name><surname>Ng</surname><given-names>HK</given-names></name><name><surname>Pfister</surname><given-names>SM</given-names></name><name><surname>Reifenberger</surname><given-names>G</given-names></name><name><surname>Soffietti</surname><given-names>R</given-names></name><name><surname>von Deimling</surname><given-names>A</given-names></name><name><surname>Ellison</surname><given-names>DW</given-names></name></person-group><article-title>The 2021 WHO classification of tumors of the central nervous system: a summary</article-title><source>Neuro Oncol</source><year>2021</year><volume>23</volume><fpage>1231</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1093/neuonc/noab106</pub-id><pub-id pub-id-type="pmid">34185076</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231&#x02013;1251. 10.1093/neuonc/noab106<pub-id pub-id-type="pmid">34185076</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Shavers</surname><given-names>VL</given-names></name></person-group><article-title>Measurement of socioeconomic status in health disparities research</article-title><source>J Natl Med Assoc</source><year>2007</year><volume>99</volume><fpage>1013</fpage><lpage>1023</lpage><pub-id pub-id-type="pmid">17913111</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Shavers VL (2007) Measurement of socioeconomic status in health disparities research. J Natl Med Assoc 99:1013&#x02013;1023<pub-id pub-id-type="pmid">17913111</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Cote</surname><given-names>DJ</given-names></name><name><surname>Ostrom</surname><given-names>QT</given-names></name><name><surname>Gittleman</surname><given-names>H</given-names></name><name><surname>Duncan</surname><given-names>KR</given-names></name><name><surname>CreveCoeur</surname><given-names>TS</given-names></name><name><surname>Kruchko</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>TR</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Barnholtz-Sloan</surname><given-names>JS</given-names></name></person-group><article-title>Glioma incidence and survival variations by county-level socioeconomic measures</article-title><source>Cancer</source><year>2019</year><volume>125</volume><fpage>3390</fpage><lpage>3400</lpage><pub-id pub-id-type="doi">10.1002/cncr.32328</pub-id><pub-id pub-id-type="pmid">31206646</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Cote DJ, Ostrom QT, Gittleman H, Duncan KR, CreveCoeur TS, Kruchko C, Smith TR, Stampfer MJ, Barnholtz-Sloan JS (2019) Glioma incidence and survival variations by county-level socioeconomic measures. Cancer 125:3390&#x02013;3400. 10.1002/cncr.32328<pub-id pub-id-type="pmid">31206646</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Khanolkar</surname><given-names>AR</given-names></name><name><surname>Ljung</surname><given-names>R</given-names></name><name><surname>Talback</surname><given-names>M</given-names></name><name><surname>Brooke</surname><given-names>HL</given-names></name><name><surname>Carlsson</surname><given-names>S</given-names></name><name><surname>Mathiesen</surname><given-names>T</given-names></name><name><surname>Feychting</surname><given-names>M</given-names></name></person-group><article-title>Socioeconomic position and the risk of brain tumour: a Swedish national population-based cohort study</article-title><source>J Epidemiol Community Health</source><year>2016</year><volume>70</volume><fpage>1222</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1136/jech-2015-207002</pub-id><pub-id pub-id-type="pmid">27325866</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Khanolkar AR, Ljung R, Talback M, Brooke HL, Carlsson S, Mathiesen T, Feychting M (2016) Socioeconomic position and the risk of brain tumour: a Swedish national population-based cohort study. J Epidemiol Community Health 70:1222&#x02013;1228. 10.1136/jech-2015-207002<pub-id pub-id-type="pmid">27325866</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Dalton</surname><given-names>SO</given-names></name><name><surname>Schuz</surname><given-names>J</given-names></name><name><surname>Engholm</surname><given-names>G</given-names></name><name><surname>Johansen</surname><given-names>C</given-names></name><name><surname>Kjaer</surname><given-names>SK</given-names></name><name><surname>Steding-Jessen</surname><given-names>M</given-names></name><name><surname>Storm</surname><given-names>HH</given-names></name><name><surname>Olsen</surname><given-names>JH</given-names></name></person-group><article-title>Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994&#x02013;2003: summary of findings</article-title><source>Eur J Cancer</source><year>2008</year><volume>44</volume><fpage>2074</fpage><lpage>2085</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2008.06.018</pub-id><pub-id pub-id-type="pmid">18674895</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Dalton SO, Schuz J, Engholm G, Johansen C, Kjaer SK, Steding-Jessen M, Storm HH, Olsen JH (2008) Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994&#x02013;2003: summary of findings. Eur J Cancer 44:2074&#x02013;2085. 10.1016/j.ejca.2008.06.018<pub-id pub-id-type="pmid">18674895</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>J</given-names></name><name><surname>Holgersson</surname><given-names>G</given-names></name><name><surname>Jaras</surname><given-names>J</given-names></name><name><surname>Bergstrom</surname><given-names>S</given-names></name><name><surname>Bergqvist</surname><given-names>M</given-names></name></person-group><article-title>The role of income in brain tumor patients: a descriptive register-based study : No correlation between patients&#x02019; income and development of brain cancer</article-title><source>Med Oncol</source><year>2018</year><volume>35</volume><fpage>52</fpage><pub-id pub-id-type="doi">10.1007/s12032-018-1108-5</pub-id><pub-id pub-id-type="pmid">29532282</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Nilsson J, Holgersson G, Jaras J, Bergstrom S, Bergqvist M (2018) The role of income in brain tumor patients: a descriptive register-based study&#x0202f;: No correlation between patients&#x02019; income and development of brain cancer. Med Oncol 35:52. 10.1007/s12032-018-1108-5<pub-id pub-id-type="pmid">29532282</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Dressler</surname><given-names>EV</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Garcia</surname><given-names>CR</given-names></name><name><surname>Dolecek</surname><given-names>TA</given-names></name><name><surname>Pittman</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Villano</surname><given-names>JL</given-names></name></person-group><article-title>Patterns and disparities of care in glioblastoma</article-title><source>Neurooncol Pract</source><year>2019</year><volume>6</volume><fpage>37</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1093/nop/npy014</pub-id><pub-id pub-id-type="pmid">30740232</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Dressler EV, Liu M, Garcia CR, Dolecek TA, Pittman T, Huang B, Villano JL (2019) Patterns and disparities of care in glioblastoma. Neurooncol Pract 6:37&#x02013;46. 10.1093/nop/npy014<pub-id pub-id-type="pmid">30740232</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>EV</given-names></name><name><surname>Ross</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Smith</surname><given-names>TR</given-names></name><name><surname>Davis</surname><given-names>FG</given-names></name></person-group><article-title>Brain Cancer Survival in Canada 1996&#x02013;2008: effects of sociodemographic characteristics</article-title><source>Curr Oncol</source><year>2019</year><volume>26</volume><fpage>292</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.3747/co.26.4273</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Walker EV, Ross J, Yuan Y, Smith TR, Davis FG (2019) Brain Cancer Survival in Canada 1996&#x02013;2008: effects of sociodemographic characteristics. Curr Oncol 26:292&#x02013;299. 10.3747/co.26.4273</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Zucca</surname><given-names>A</given-names></name><name><surname>Boyes</surname><given-names>A</given-names></name><name><surname>Newling</surname><given-names>G</given-names></name><name><surname>Hall</surname><given-names>A</given-names></name><name><surname>Girgis</surname><given-names>A</given-names></name></person-group><article-title>Travelling all over the countryside: travel-related burden and financial difficulties reported by cancer patients in New South Wales and Victoria</article-title><source>Aust J Rural Health</source><year>2011</year><volume>19</volume><fpage>298</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1584.2011.01232.x</pub-id><pub-id pub-id-type="pmid">22098213</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Zucca A, Boyes A, Newling G, Hall A, Girgis A (2011) Travelling all over the countryside: travel-related burden and financial difficulties reported by cancer patients in New South Wales and Victoria. Aust J Rural Health 19:298&#x02013;305. 10.1111/j.1440-1584.2011.01232.x<pub-id pub-id-type="pmid">22098213</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>AC</given-names></name><name><surname>Levy</surname><given-names>MA</given-names></name></person-group><article-title>Determining burden of commuting for treatment using online mapping services - a study of breast cancer patients</article-title><source>AMIA Annu Symp Proc</source><year>2017</year><volume>2017</volume><fpage>555</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">29854120</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Cheng AC, Levy MA (2017) Determining burden of commuting for treatment using online mapping services - a study of breast cancer patients. AMIA Annu Symp Proc 2017:555&#x02013;564<pub-id pub-id-type="pmid">29854120</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Jirka</surname><given-names>GW</given-names></name><name><surname>Bisselou</surname><given-names>KSM</given-names></name><name><surname>Smith</surname><given-names>LM</given-names></name><name><surname>Shonka</surname><given-names>N</given-names></name></person-group><article-title>Evaluating the decisions of glioma patients regarding clinical trial participation: a retrospective single provider review</article-title><source>Med Oncol</source><year>2019</year><volume>36</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.1007/s12032-019-1259-z</pub-id><pub-id pub-id-type="pmid">30840157</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Jirka GW, Bisselou KSM, Smith LM, Shonka N (2019) Evaluating the decisions of glioma patients regarding clinical trial participation: a retrospective single provider review. Med Oncol 36:34. 10.1007/s12032-019-1259-z<pub-id pub-id-type="pmid">30840157</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Aizer</surname><given-names>AA</given-names></name><name><surname>Chen</surname><given-names>MH</given-names></name><name><surname>McCarthy</surname><given-names>EP</given-names></name><name><surname>Mendu</surname><given-names>ML</given-names></name><name><surname>Koo</surname><given-names>S</given-names></name><name><surname>Wilhite</surname><given-names>TJ</given-names></name><name><surname>Graham</surname><given-names>PL</given-names></name><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Hoffman</surname><given-names>KE</given-names></name><name><surname>Martin</surname><given-names>NE</given-names></name><name><surname>Hu</surname><given-names>JC</given-names></name><name><surname>Nguyen</surname><given-names>PL</given-names></name></person-group><article-title>Marital status and survival in patients with cancer</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>3869</fpage><lpage>3876</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.49.6489</pub-id><pub-id pub-id-type="pmid">24062405</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Aizer AA, Chen MH, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, Graham PL, Choueiri TK, Hoffman KE, Martin NE, Hu JC, Nguyen PL (2013) Marital status and survival in patients with cancer. J Clin Oncol 31:3869&#x02013;3876. 10.1200/JCO.2013.49.6489<pub-id pub-id-type="pmid">24062405</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>JC</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>XY</given-names></name><name><surname>Zhao</surname><given-names>YX</given-names></name></person-group><article-title>Effect of marital status on survival in glioblastoma multiforme by demographics, education, economic factors, and insurance status</article-title><source>Cancer Med</source><year>2018</year><volume>7</volume><fpage>3722</fpage><lpage>3742</lpage><pub-id pub-id-type="doi">10.1002/cam4.1688</pub-id><pub-id pub-id-type="pmid">30009575</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Xie JC, Yang S, Liu XY, Zhao YX (2018) Effect of marital status on survival in glioblastoma multiforme by demographics, education, economic factors, and insurance status. Cancer Med 7:3722&#x02013;3742. 10.1002/cam4.1688<pub-id pub-id-type="pmid">30009575</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Statistical Database, Cancer. The National Board of Health and Welfare. <ext-link ext-link-type="uri" xlink:href="https://sdb.socialstyrelsen.se/if_can/val_eng.aspx">https://sdb.socialstyrelsen.se/if_can/val_eng.aspx</ext-link>. Accessed 5 May 2021</mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Educational attainment of the population. <ext-link ext-link-type="uri" xlink:href="https://www.scb.se/en/finding-statistics/statistics-by-subject-area/education-and-research/education-of-the-population/educational-attainment-of-the-population/">https://www.scb.se/en/finding-statistics/statistics-by-subject-area/education-and-research/education-of-the-population/educational-attainment-of-the-population/</ext-link>. Accessed 6 May 2021</mixed-citation></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Ohgaki</surname><given-names>H</given-names></name><name><surname>Wiestler</surname><given-names>OD</given-names></name><name><surname>Cavenee</surname><given-names>WK</given-names></name><name><surname>Burger</surname><given-names>PC</given-names></name><name><surname>Jouvet</surname><given-names>A</given-names></name><name><surname>Scheithauer</surname><given-names>BW</given-names></name><name><surname>Kleihues</surname><given-names>P</given-names></name></person-group><article-title>The 2007 WHO classification of tumours of the central nervous system</article-title><source>Acta Neuropathol</source><year>2007</year><volume>114</volume><fpage>97</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1007/s00401-007-0243-4</pub-id><pub-id pub-id-type="pmid">17618441</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97&#x02013;109. 10.1007/s00401-007-0243-4<pub-id pub-id-type="pmid">17618441</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Asklund</surname><given-names>T</given-names></name><name><surname>Malmstrom</surname><given-names>A</given-names></name><name><surname>Bergqvist</surname><given-names>M</given-names></name><name><surname>Bjor</surname><given-names>O</given-names></name><name><surname>Henriksson</surname><given-names>R</given-names></name></person-group><article-title>Brain tumors in Sweden: data from a population-based registry 1999&#x02013;2012</article-title><source>Acta Oncol</source><year>2015</year><volume>54</volume><fpage>377</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.3109/0284186X.2014.975369</pub-id><pub-id pub-id-type="pmid">25383446</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Asklund T, Malmstrom A, Bergqvist M, Bjor O, Henriksson R (2015) Brain tumors in Sweden: data from a population-based registry 1999&#x02013;2012. Acta Oncol 54:377&#x02013;384. 10.3109/0284186X.2014.975369<pub-id pub-id-type="pmid">25383446</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">The Swedish National Quality Registry for Brain Tumors. National report 1999&#x02013;2017. (Nationellt kvalitetsregister f&#x000f6;r Hj&#x000e4;rntum&#x000f6;rer, Nationell rapport 1999&#x02013;2017). <ext-link ext-link-type="uri" xlink:href="https://cancercentrum.se/globalassets/cancerdiagnoser/hjarna-cns/kvalitetsregister/ht_arsrapport_2018.pdf">https://cancercentrum.se/globalassets/cancerdiagnoser/hjarna-cns/kvalitetsregister/ht_arsrapport_2018.pdf</ext-link>. Accessed 11 Oct 2021</mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">WHO. International Statistical Classification of Diseases and Related Health Problems. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/classifications/icd/en/">http://www.who.int/classifications/icd/en/</ext-link>. Accessed 13 Nov 2023</mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Oken</surname><given-names>MM</given-names></name><name><surname>Creech</surname><given-names>RH</given-names></name><name><surname>Tormey</surname><given-names>DC</given-names></name><name><surname>Horton</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>TE</given-names></name><name><surname>McFadden</surname><given-names>ET</given-names></name><name><surname>Carbone</surname><given-names>PP</given-names></name></person-group><article-title>Toxicity and response criteria of the Eastern Cooperative Oncology Group</article-title><source>Am J Clin Oncol</source><year>1982</year><volume>5</volume><fpage>649</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1097/00000421-198212000-00014</pub-id><pub-id pub-id-type="pmid">7165009</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649&#x02013;655. 10.1097/00000421-198212000-00014<pub-id pub-id-type="pmid">7165009</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Sjostrom</surname><given-names>O</given-names></name><name><surname>Silander</surname><given-names>G</given-names></name><name><surname>Syk</surname><given-names>I</given-names></name><name><surname>Henriksson</surname><given-names>R</given-names></name><name><surname>Melin</surname><given-names>B</given-names></name><name><surname>Hellquist</surname><given-names>BN</given-names></name></person-group><article-title>Disparities in colorectal cancer between Northern and SouthernSweden - a report from the new RISK North database</article-title><source>Acta Oncol</source><year>2018</year><volume>57</volume><fpage>1622</fpage><lpage>1630</lpage><pub-id pub-id-type="doi">10.1080/0284186X.2018.1497300</pub-id><pub-id pub-id-type="pmid">30280619</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Sjostrom O, Silander G, Syk I, Henriksson R, Melin B, Hellquist BN (2018) Disparities in colorectal cancer between Northern and SouthernSweden - a report from the new RISK North database. Acta Oncol 57:1622&#x02013;1630. 10.1080/0284186X.2018.1497300<pub-id pub-id-type="pmid">30280619</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Ludvigsson</surname><given-names>JF</given-names></name><name><surname>Almqvist</surname><given-names>C</given-names></name><name><surname>Bonamy</surname><given-names>AK</given-names></name><name><surname>Ljung</surname><given-names>R</given-names></name><name><surname>Michaelsson</surname><given-names>K</given-names></name><name><surname>Neovius</surname><given-names>M</given-names></name><name><surname>Stephansson</surname><given-names>O</given-names></name><name><surname>Ye</surname><given-names>W</given-names></name></person-group><article-title>Registers of the Swedish total population and their use in medical research</article-title><source>Eur J Epidemiol</source><year>2016</year><volume>31</volume><fpage>125</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1007/s10654-016-0117-y</pub-id><pub-id pub-id-type="pmid">26769609</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Ludvigsson JF, Almqvist C, Bonamy AK, Ljung R, Michaelsson K, Neovius M, Stephansson O, Ye W (2016) Registers of the Swedish total population and their use in medical research. Eur J Epidemiol 31:125&#x02013;136. 10.1007/s10654-016-0117-y<pub-id pub-id-type="pmid">26769609</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Ludvigsson</surname><given-names>JF</given-names></name><name><surname>Svedberg</surname><given-names>P</given-names></name><name><surname>Olen</surname><given-names>O</given-names></name><name><surname>Bruze</surname><given-names>G</given-names></name><name><surname>Neovius</surname><given-names>M</given-names></name></person-group><article-title>The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research</article-title><source>Eur J Epidemiol</source><year>2019</year><volume>34</volume><fpage>423</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1007/s10654-019-00511-8</pub-id><pub-id pub-id-type="pmid">30929112</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Ludvigsson JF, Svedberg P, Olen O, Bruze G, Neovius M (2019) The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur J Epidemiol 34:423&#x02013;437. 10.1007/s10654-019-00511-8<pub-id pub-id-type="pmid">30929112</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">UNESCO Institute for Statistics (2012) International Standard Classification of Education ISCED 2011. <ext-link ext-link-type="uri" xlink:href="https://uis.unesco.org/sites/default/files/documents/">https://uis.unesco.org/sites/default/files/documents/</ext-link>international-standard-classification-of-education-isced-2011-en.pdf. Accessed 22 Mar 2023</mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">R Core Team (2019) R: A language and environment for statistical computing. 1&#x02013;105. <ext-link ext-link-type="uri" xlink:href="https://www.R-project.org/">https://www.R-project.org/</ext-link>. Accessed 21 Dec 2020</mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Lacroix</surname><given-names>M</given-names></name><name><surname>Abi-Said</surname><given-names>D</given-names></name><name><surname>Fourney</surname><given-names>DR</given-names></name><name><surname>Gokaslan</surname><given-names>ZL</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>DeMonte</surname><given-names>F</given-names></name><name><surname>Lang</surname><given-names>FF</given-names></name><name><surname>McCutcheon</surname><given-names>IE</given-names></name><name><surname>Hassenbusch</surname><given-names>SJ</given-names></name><name><surname>Holland</surname><given-names>E</given-names></name><name><surname>Hess</surname><given-names>K</given-names></name><name><surname>Michael</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name><name><surname>Sawaya</surname><given-names>R</given-names></name></person-group><article-title>A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival</article-title><source>J Neurosurg</source><year>2001</year><volume>95</volume><fpage>190</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.3171/jns.2001.95.2.0190</pub-id><pub-id pub-id-type="pmid">11780887</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190&#x02013;198. 10.3171/jns.2001.95.2.0190<pub-id pub-id-type="pmid">11780887</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Esteller</surname><given-names>M</given-names></name><name><surname>Garcia-Foncillas</surname><given-names>J</given-names></name><name><surname>Andion</surname><given-names>E</given-names></name><name><surname>Goodman</surname><given-names>SN</given-names></name><name><surname>Hidalgo</surname><given-names>OF</given-names></name><name><surname>Vanaclocha</surname><given-names>V</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name></person-group><article-title>Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>1350</fpage><lpage>1354</lpage><pub-id pub-id-type="doi">10.1056/NEJM200011093431901</pub-id><pub-id pub-id-type="pmid">11070098</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350&#x02013;1354. 10.1056/NEJM200011093431901<pub-id pub-id-type="pmid">11070098</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Laws</surname><given-names>ER</given-names></name><name><surname>Parney</surname><given-names>IF</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Anderson</surname><given-names>F</given-names></name><name><surname>Morris</surname><given-names>AM</given-names></name><name><surname>Asher</surname><given-names>A</given-names></name><name><surname>Lillehei</surname><given-names>KO</given-names></name><name><surname>Bernstein</surname><given-names>M</given-names></name><name><surname>Brem</surname><given-names>H</given-names></name><name><surname>Sloan</surname><given-names>A</given-names></name><name><surname>Berger</surname><given-names>MS</given-names></name><name><surname>Chang</surname><given-names>S</given-names></name><name><surname>Glioma Outcomes</surname><given-names>I</given-names></name></person-group><article-title>Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project</article-title><source>J Neurosurg</source><year>2003</year><volume>99</volume><fpage>467</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.3171/jns.2003.99.3.0467</pub-id><pub-id pub-id-type="pmid">12959431</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan A, Berger MS, Chang S, Glioma Outcomes I (2003) Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 99:467&#x02013;473. 10.3171/jns.2003.99.3.0467<pub-id pub-id-type="pmid">12959431</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Hegi</surname><given-names>ME</given-names></name><name><surname>Diserens</surname><given-names>AC</given-names></name><name><surname>Godard</surname><given-names>S</given-names></name><name><surname>Dietrich</surname><given-names>PY</given-names></name><name><surname>Regli</surname><given-names>L</given-names></name><name><surname>Ostermann</surname><given-names>S</given-names></name><name><surname>Otten</surname><given-names>P</given-names></name><name><surname>Van Melle</surname><given-names>G</given-names></name><name><surname>de Tribolet</surname><given-names>N</given-names></name><name><surname>Stupp</surname><given-names>R</given-names></name></person-group><article-title>Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>1871</fpage><lpage>1874</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.ccr-03-0384</pub-id><pub-id pub-id-type="pmid">15041700</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871&#x02013;1874. 10.1158/1078-0432.ccr-03-0384<pub-id pub-id-type="pmid">15041700</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>DW</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>JC</given-names></name><name><surname>Leary</surname><given-names>RJ</given-names></name><name><surname>Angenendt</surname><given-names>P</given-names></name><name><surname>Mankoo</surname><given-names>P</given-names></name><name><surname>Carter</surname><given-names>H</given-names></name><name><surname>Siu</surname><given-names>IM</given-names></name><name><surname>Gallia</surname><given-names>GL</given-names></name><name><surname>Olivi</surname><given-names>A</given-names></name><name><surname>McLendon</surname><given-names>R</given-names></name><name><surname>Rasheed</surname><given-names>BA</given-names></name><name><surname>Keir</surname><given-names>S</given-names></name><name><surname>Nikolskaya</surname><given-names>T</given-names></name><name><surname>Nikolsky</surname><given-names>Y</given-names></name><name><surname>Busam</surname><given-names>DA</given-names></name><name><surname>Tekleab</surname><given-names>H</given-names></name><name><surname>Diaz</surname><given-names>LA</given-names></name><name><surname>Hartigan</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>DR</given-names></name><name><surname>Strausberg</surname><given-names>RL</given-names></name><name><surname>Marie</surname><given-names>SK</given-names></name><name><surname>Shinjo</surname><given-names>SM</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Riggins</surname><given-names>GJ</given-names></name><name><surname>Bigner</surname><given-names>DD</given-names></name><name><surname>Karchin</surname><given-names>R</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Parmigiani</surname><given-names>G</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><article-title>An integrated genomic analysis of human glioblastoma multiforme</article-title><source>Science</source><year>2008</year><volume>321</volume><fpage>1807</fpage><lpage>1812</lpage><pub-id pub-id-type="doi">10.1126/science.1164382</pub-id><pub-id pub-id-type="pmid">18772396</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807&#x02013;1812. 10.1126/science.1164382<pub-id pub-id-type="pmid">18772396</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsitlakidis</surname><given-names>A</given-names></name><name><surname>Foroglou</surname><given-names>N</given-names></name><name><surname>Venetis</surname><given-names>CA</given-names></name><name><surname>Patsalas</surname><given-names>I</given-names></name><name><surname>Hatzisotiriou</surname><given-names>A</given-names></name><name><surname>Selviaridis</surname><given-names>P</given-names></name></person-group><article-title>Biopsy versus resection in the management of malignant gliomas: a systematic review and meta-analysis</article-title><source>J Neurosurg</source><year>2010</year><volume>112</volume><fpage>1020</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.3171/2009.7.JNS09758</pub-id><pub-id pub-id-type="pmid">19747048</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Tsitlakidis A, Foroglou N, Venetis CA, Patsalas I, Hatzisotiriou A, Selviaridis P (2010) Biopsy versus resection in the management of malignant gliomas: a systematic review and meta-analysis. J Neurosurg 112:1020&#x02013;1032. 10.3171/2009.7.JNS09758<pub-id pub-id-type="pmid">19747048</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Kawano</surname><given-names>H</given-names></name><name><surname>Hirano</surname><given-names>H</given-names></name><name><surname>Yonezawa</surname><given-names>H</given-names></name><name><surname>Yunoue</surname><given-names>S</given-names></name><name><surname>Yatsushiro</surname><given-names>K</given-names></name><name><surname>Ogita</surname><given-names>M</given-names></name><name><surname>Hiraki</surname><given-names>Y</given-names></name><name><surname>Uchida</surname><given-names>H</given-names></name><name><surname>Habu</surname><given-names>M</given-names></name><name><surname>Fujio</surname><given-names>S</given-names></name><name><surname>Oyoshi</surname><given-names>T</given-names></name><name><surname>Bakhtiar</surname><given-names>Y</given-names></name><name><surname>Sugata</surname><given-names>S</given-names></name><name><surname>Yamahata</surname><given-names>H</given-names></name><name><surname>Hanaya</surname><given-names>R</given-names></name><name><surname>Tokimura</surname><given-names>H</given-names></name><name><surname>Arita</surname><given-names>K</given-names></name></person-group><article-title>Improvement in treatment results of glioblastoma over the last three decades and beneficial factors</article-title><source>Br J Neurosurg</source><year>2015</year><volume>29</volume><fpage>206</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.3109/02688697.2014.967750</pub-id><pub-id pub-id-type="pmid">25311043</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Kawano H, Hirano H, Yonezawa H, Yunoue S, Yatsushiro K, Ogita M, Hiraki Y, Uchida H, Habu M, Fujio S, Oyoshi T, Bakhtiar Y, Sugata S, Yamahata H, Hanaya R, Tokimura H, Arita K (2015) Improvement in treatment results of glioblastoma over the last three decades and beneficial factors. Br J Neurosurg 29:206&#x02013;212. 10.3109/02688697.2014.967750<pub-id pub-id-type="pmid">25311043</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>M</given-names></name><name><surname>Kahari</surname><given-names>J</given-names></name><name><surname>Vestman</surname><given-names>A</given-names></name><name><surname>Hallmans</surname><given-names>M</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Bergenheim</surname><given-names>AT</given-names></name><name><surname>Sandstrom</surname><given-names>M</given-names></name></person-group><article-title>Improved treatment of glioblastoma - changes in survival over two decades at a single regional Centre</article-title><source>Acta Oncol</source><year>2019</year><volume>58</volume><fpage>334</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1080/0284186X.2019.1571278</pub-id><pub-id pub-id-type="pmid">30732527</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Eriksson M, Kahari J, Vestman A, Hallmans M, Johansson M, Bergenheim AT, Sandstrom M (2019) Improved treatment of glioblastoma - changes in survival over two decades at a single regional Centre. Acta Oncol 58:334&#x02013;341. 10.1080/0284186X.2019.1571278<pub-id pub-id-type="pmid">30732527</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R</given-names></name><name><surname>Hegi</surname><given-names>ME</given-names></name><name><surname>Mason</surname><given-names>WP</given-names></name><name><surname>van den Bent</surname><given-names>MJ</given-names></name><name><surname>Taphoorn</surname><given-names>MJ</given-names></name><name><surname>Janzer</surname><given-names>RC</given-names></name><name><surname>Ludwin</surname><given-names>SK</given-names></name><name><surname>Allgeier</surname><given-names>A</given-names></name><name><surname>Fisher</surname><given-names>B</given-names></name><name><surname>Belanger</surname><given-names>K</given-names></name><name><surname>Hau</surname><given-names>P</given-names></name><name><surname>Brandes</surname><given-names>AA</given-names></name><name><surname>Gijtenbeek</surname><given-names>J</given-names></name><name><surname>Marosi</surname><given-names>C</given-names></name><name><surname>Vecht</surname><given-names>CJ</given-names></name><name><surname>Mokhtari</surname><given-names>K</given-names></name><name><surname>Wesseling</surname><given-names>P</given-names></name><name><surname>Villa</surname><given-names>S</given-names></name><name><surname>Eisenhauer</surname><given-names>E</given-names></name><name><surname>Gorlia</surname><given-names>T</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name><name><surname>Lacombe</surname><given-names>D</given-names></name><name><surname>Cairncross</surname><given-names>JG</given-names></name><name><surname>Mirimanoff</surname><given-names>RO</given-names></name><collab>European Organisation for R</collab><collab>Treatment of Cancer Brain T</collab><collab>Radiation Oncology G</collab><collab>National Cancer Institute of Canada Clinical Trials G</collab></person-group><article-title>Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial</article-title><source>Lancet Oncol</source><year>2009</year><volume>10</volume><fpage>459</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(09)70025-7</pub-id><pub-id pub-id-type="pmid">19269895</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiation Oncology G, National Cancer Institute of Canada Clinical Trials G (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459&#x02013;466. 10.1016/S1470-2045(09)70025-7<pub-id pub-id-type="pmid">19269895</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Carstam</surname><given-names>L</given-names></name><name><surname>Ryden</surname><given-names>I</given-names></name><name><surname>Gulati</surname><given-names>S</given-names></name><name><surname>Rydenhag</surname><given-names>B</given-names></name><name><surname>Henriksson</surname><given-names>R</given-names></name><name><surname>Salvesen</surname><given-names>O</given-names></name><name><surname>Smits</surname><given-names>A</given-names></name><name><surname>Jakola</surname><given-names>AS</given-names></name></person-group><article-title>Socioeconomic factors affect treatment delivery for patients with low grade glioma: a Swedish population-based study</article-title><source>J Neurooncol</source><year>2020</year><volume>146</volume><fpage>329</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1007/s11060-019-03378-7</pub-id><pub-id pub-id-type="pmid">31883050</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Carstam L, Ryden I, Gulati S, Rydenhag B, Henriksson R, Salvesen O, Smits A, Jakola AS (2020) Socioeconomic factors affect treatment delivery for patients with low grade glioma: a Swedish population-based study. J Neurooncol 146:329&#x02013;337. 10.1007/s11060-019-03378-7<pub-id pub-id-type="pmid">31883050</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>CG</given-names></name><name><surname>Wyszewianski</surname><given-names>L</given-names></name></person-group><article-title>Access to care: remembering old lessons</article-title><source>Health Serv Res</source><year>2002</year><volume>37</volume><fpage>1441</fpage><lpage>1443</lpage><pub-id pub-id-type="doi">10.1111/1475-6773.12171</pub-id><pub-id pub-id-type="pmid">12546280</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">McLaughlin CG, Wyszewianski L (2002) Access to care: remembering old lessons. Health Serv Res 37:1441&#x02013;1443. 10.1111/1475-6773.12171<pub-id pub-id-type="pmid">12546280</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Svendsen</surname><given-names>RP</given-names></name><name><surname>Jarbol</surname><given-names>DE</given-names></name><name><surname>Larsen</surname><given-names>PV</given-names></name><name><surname>Stovring</surname><given-names>H</given-names></name><name><surname>Hansen</surname><given-names>BL</given-names></name><name><surname>Soendergaard</surname><given-names>J</given-names></name></person-group><article-title>Associations between health care seeking and socioeconomic and demographic determinants among people reporting alarm symptoms of cancer: a population-based cross-sectional study</article-title><source>Fam Pract</source><year>2013</year><volume>30</volume><fpage>655</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1093/fampra/cmt036</pub-id><pub-id pub-id-type="pmid">23864364</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Svendsen RP, Jarbol DE, Larsen PV, Stovring H, Hansen BL, Soendergaard J (2013) Associations between health care seeking and socioeconomic and demographic determinants among people reporting alarm symptoms of cancer: a population-based cross-sectional study. Fam Pract 30:655&#x02013;665. 10.1093/fampra/cmt036<pub-id pub-id-type="pmid">23864364</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>